Answers are grounded in this paper and cite their sources.
We began to use single dose rituximab in 2002 as a part of an immunosuppressive protocol for ABO-incompatible renal transplantation (1). When analyzing the outcome of the first 20 cases in 2005 (2), we were surprised to find that the results with ABO-incompatible transplantations were equal or superior to those of ABO-compatible transplantations. Especially, there were no cellular rejection episodes at all in the ABO-incompatible group. Because the only difference between the immunosuppressive treatment given to ABO-incompatible kidney recipients and that given to ABO-compatible kidney recipients was the addition of rituximab, we hypothesized that the low incidence of rejection episodes in the ABO-incompatible group was because of the rituximab induction. In 2008, we therefore performed a prospective, randomized, double-blind, placebo-controlled, multicenter study of the efficacy and safety of rituximab as induction therapy in combination with a conventional immunosuppressive protocol (3). This is a 3-year follow follow-up of those patients. In the study group, 44 of 68 patients were available for follow-up at 3 years. One graft had been lost in chronic rejection, 8 patients had died, and 15 declined participation. Of those 44, it was possible to perform a Luminex antibody test to detect donor-specific antibodies in 33 (in one center the Luminex test was not available). One of those 33 had developed donor-specific antibodies (both class I and class II). In the placebo group, 47 of 68 patients were available for follow-up at 3 years. One graft had been lost in recurrence of the disease, and 20 patients declined participation. Of those 47, testing for donor-specific antibodies was performed in 38, 6 of whom had developed donor-specific antibodies (6 class I and in 3 class II as well). The difference in mortality (8/68 vs. 0/68) was statistically significant (P=0.006). The mortality was attributed to fungal pneumonia (in one case), pulmonary carcinoma (in one case), and myocardial infarction/cardiac arrests in six cases. The difference in the development of donor-specific antibodies was not significant (P=0.10). There was no difference between the study group and the placebo group regarding demographics (gender, age, prevalence of cardiovascular disease, body weight, and body surface area) or bacterial, fungal, cytomegalovirus, or polyoma infections. In the initial study, the primary endpoint was defined as acute rejection, graft loss, or death during the first 6 months. There were 10 treatment failures in the study group versus 14 in the placebo group (P=0.34). There were 8 rejection episodes in the study group versus 12 in the placebo group (P=0.31). The conclusion was that there was a tendency toward fewer and milder rejections during the first 6 months in the study group. In the present 3-year follow-up, our main focus was on the development of donor-specific antibodies and the possible implications of that on long-term graft survival. We did find a difference in the development of donor-specific antibodies. However, probably because of the high number of drop-outs, this difference did not prove to be significant. There was no difference in the number of graft losses because of late rejection between the groups. Somewhat surprising was the statistically significant difference in mortality with eight deaths in the study group versus none in the placebo group. Although a high mortality rate has indeed been reported elsewhere after rituximab treatment in transplantation patients (4), this was in patients having received repeated doses of rituximab, and all were infection-related deaths. In the present study, the deaths were mainly related to cardiovascular events. This may be explained by the fact that B cells may play an atheroprotective role (5), and the depletion of B cells could therefore enhance the development of cardiovascular disease. It was reassuring that we could not find any differences between the study group and the placebo group regarding bacterial infections, fungal infections, cytomegalovirus, or polyomavirus infections. Gunnar Tydén 1 Henrik Ekberg2 Gunnar Tufveson3 Lars Mjörnstedt4 1 Department of Transplantation Surgery Karolinska University Hospital Stockholm, Sweden 2 Department of Transplantation Surgery Malmoe University Hospital Malmoe, Sweden 3 Department of Transplantation Surgery Uppsala Academic Hospital Uppsala, Sweden 4 Department of Transplantation Surgery Sahlgrenska University Hospital Gothenburg, Sweden
No takes yet. Share an insight, caveat, or question.
Tydén et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: